Article: NeoTherapeutics Expands Neotrofin(TM) Spinal Cord Injury Trial.

Phase 2 study in paraplegic and quadriplegic spinal cord

injury patients is set to begin enrollment at a second site

IRVINE, Calif., June 29 /PRNewswire/ --

NeoTherapeutics, Inc. (Nasdaq: NEOT; NEOTW) announced today that it has expanded its Neotrofin spinal cord injury trial to include Gaylord Hospital in Wallingford, Connecticut. Gaylord Hospital, which is affiliated with Yale University and the University of Connecticut, is the second site participating in the spinal cord injury trial. Additional sites are expected to join the study over the next couple of months. The 12-week open-label study of Neotrofin in patients with subacute complete ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!